Posted by Michael Wonder on 19 Oct 2016
EMA updates list of PRIME priority medicines
19 October 2016 - The EMA has added three new technologies to the list following last week's CHMP meeting.
PRIME is a scheme launched by the EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier.
Through PRIME, the Agency offers early and proactive support to medicine developers to optimise the generation of robust data on a medicine’s benefits and risks and enable accelerated assessment of medicines applications.
